The Role of Leukotriene Modifiers in the Management of Exercise-Induced Bronchoconstriction

Author:

Kelly Charles B1,Rodgers Philip T2

Affiliation:

1. Martha Washington Hospital, Charlottesville, VA

2. Duke University Health System, Durham, NC; and School of Pharmacy, The University of North Carolina

Abstract

Objective To review the use of leukotriene modifiers in exercise-induced bronchoconstriction (EIB). Data Source A MEDLINE search (1966–March 2001) identified pertinent English-language publications on EIB in humans. Study Selection Selection of prospective clinical studies was limited to those that focused on prevention of EIB with leukotriene modifiers, including both leukotriene receptor antagonists and 5-lipoxygenase inhibitors. Data Synthesis Leukotriene modifiers have been shown to attenuate EIB in patients with mild to intermittent, stable asthma from exacerbations after exercise, especially those with a predicted forced expiratory volume in 1 second (FEV1) >80% and who did not require corticosteroids. Extrapolation to patients with more severe forms of asthma cannot be made because of the lack of currently available data in these types of patients. Children may benefit from the oral dosage forms of leukotriene modifiers if they have difficulty using a metered-dose inhaler. The current literature supports a lack of a tolerance effect with leukotriene modifiers, as opposed to tachyphylaxis seen with beta2-adrenergic drugs after repeated dosing. As many as 25% of EIB patients will not respond to therapy with leukotriene modifiers. Montelukast has the greatest volume of data and the most positive benefits of the available leukotriene modifiers. Conclusions Evidence supports the use of leukotriene modifiers for protection of EIB in patients with stable, mild to intermittent asthma with a predicted FEV1 ≥80% if beta-agonists are intolerable or ineffective. Potential benefits include the lack of a tolerance effect, the long duration of action exhibited by some leukotriene modifiers, and the availability of a tablet form. Beta2-adrenergic drugs should remain the first-line therapy for EIB; however, leukotriene modifiers may provide a valuable alternative in those few who cannot use short-acting beta-agonists. Long-term safety studies of leukotriene modifiers in children and the elderly with EIB are necessary before widespread use can be advocated in the pediatric and geriatric populations.

Publisher

SAGE Publications

Subject

Pharmaceutical Science

Reference33 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3